Tyrosine kinase inhibitors-induced myelosuppression - case report

Abstract

This paper presents a patient with chronic myeloid leukemia (CML) in chronic phase and profound myelosuppression induced by tyrosine kinase inhibitors (TKI), included imatinib, dasatinib and nilotinib. Therapy with each of TKI was complicated by severe cytopenia, which resulted in interruptions and daily dose reduction of the drugs. Finally, myelosuppression and reduced dense-dosage of each TKI resulted in CML treatment failure. This case illustrates the therapeutic difficulties related to TKI-induced myelosuppresion in the chronic phase of CML.
Hematologia 2010; 1, 3: 249-253